Psychiatric Times articleshttps://www.psychiatrictimes.com/newsPsychiatric Times articles© 2026 MJH Life Sciences™ and Psychiatric Times. All rights reserved.Thu, 08 Oct 2026 21:15:58 +00005en-us14447https://www.psychiatrictimes.com/newshttps://www.psychiatrictimes.com/logo.webphttps://www.psychiatrictimes.com/view/clozapine-remains-underused-after-rems-elimination-a-conversation-with-jose-rubio-md-phdhttps://www.psychiatrictimes.com/view/clozapine-remains-underused-after-rems-elimination-a-conversation-with-jose-rubio-md-phd<![CDATA[Ending the REMS cut the paperwork, but reimbursement that ignores clozapine’s added care demands still keeps the drug from patients who could benefit.]]>Thu, 08 Oct 2026 17:44:09 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/are-clinicians-prepared-to-counsel-patients-about-psychedelicshttps://www.psychiatrictimes.com/view/are-clinicians-prepared-to-counsel-patients-about-psychedelics<![CDATA[Psychedelic psychiatry gains momentum as clinicians weigh evidence, safety, and stigma.]]>Thu, 08 Oct 2026 16:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/phase-1-clinical-studies-completed-ntx-253-for-the-treatment-of-schizophreniahttps://www.psychiatrictimes.com/view/phase-1-clinical-studies-completed-ntx-253-for-the-treatment-of-schizophrenia<![CDATA[Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.]]>Thu, 08 Oct 2026 14:23:01 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/podcast-a-learning-health-network-to-improve-bipolar-outcomes-with-andrew-nierenberg-mdhttps://www.psychiatrictimes.com/view/podcast-a-learning-health-network-to-improve-bipolar-outcomes-with-andrew-nierenberg-md<![CDATA[Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.]]>Thu, 08 Oct 2026 14:15:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/measurement-informed-psychiatric-care-if-not-now-then-whenhttps://www.psychiatrictimes.com/view/measurement-informed-psychiatric-care-if-not-now-then-when<![CDATA[Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.]]>Thu, 08 Oct 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/how-a-learning-health-network-could-transform-bipolar-disorder-treatment-a-conversation-with-andrew-nierenberg-mdhttps://www.psychiatrictimes.com/view/how-a-learning-health-network-could-transform-bipolar-disorder-treatment-a-conversation-with-andrew-nierenberg-md<![CDATA[Andrew A. Nierenberg, MD, explains how the Bipolar Action Network uses shared data and improvement science to change how bipolar disorder care is delivered.]]>Thu, 08 Oct 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/beyond-amyloid-and-tau-blood-testing-for-neurodegenerative-and-psychiatric-diseasehttps://www.psychiatrictimes.com/view/beyond-amyloid-and-tau-blood-testing-for-neurodegenerative-and-psychiatric-disease<![CDATA[A new blood test approach analyzes RNA inside extracellular vesicles, aiming to spot Alzheimer disease earlier.]]>Thu, 08 Oct 2026 13:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/muscarinic-treatment-for-schizophrenia-a-presynaptic-answer-to-a-presynaptic-problemhttps://www.psychiatrictimes.com/view/muscarinic-treatment-for-schizophrenia-a-presynaptic-answer-to-a-presynaptic-problem<![CDATA[Christoph U. Correll, MD, explains how a new class of muscarinic agents lowers dopamine in specific brain regions without blocking dopamine receptors.]]>Wed, 07 Oct 2026 20:01:16 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/blood-based-biomarkers-for-alzheimer-disease-accuracy-limits-and-confoundershttps://www.psychiatrictimes.com/view/blood-based-biomarkers-for-alzheimer-disease-accuracy-limits-and-confounders<![CDATA[George Grossberg, MD, reviews how accurate the first FDA-cleared Alzheimer blood test is and which patient factors can skew its results.]]>Wed, 07 Oct 2026 17:32:03 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/could-rna-in-blood-nanoparticles-enable-earlier-diagnosis-of-alzheimer-diseasehttps://www.psychiatrictimes.com/view/could-rna-in-blood-nanoparticles-enable-earlier-diagnosis-of-alzheimer-disease<![CDATA[Emerging blood RNA tests may analyze brain-derived exosomes to detect Alzheimer disease earlier.]]>Wed, 07 Oct 2026 17:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/first-patient-dosed-in-phase-2a-trial-of-glyphago-for-generalized-anxiety-disorder-and-sleep-disturbancehttps://www.psychiatrictimes.com/view/first-patient-dosed-in-phase-2a-trial-of-glyphago-for-generalized-anxiety-disorder-and-sleep-disturbance<![CDATA[Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.]]>Wed, 07 Oct 2026 16:07:31 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/fda-grants-clearance-to-motivista-the-first-authorized-treatment-for-negative-symptoms-of-schizophreniahttps://www.psychiatrictimes.com/view/fda-grants-clearance-to-motivista-the-first-authorized-treatment-for-negative-symptoms-of-schizophrenia<![CDATA[FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.]]>Wed, 07 Oct 2026 14:06:54 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/vortioxetines-effect-on-cognitive-function-in-older-adults-with-major-depressive-disorderhttps://www.psychiatrictimes.com/view/vortioxetines-effect-on-cognitive-function-in-older-adults-with-major-depressive-disorder<![CDATA[Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.]]>Wed, 07 Oct 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/when-phq-9-scores-mislead-rating-scales-and-clinical-judgmenthttps://www.psychiatrictimes.com/view/when-phq-9-scores-mislead-rating-scales-and-clinical-judgment<![CDATA[A PHQ-9 score can mislead as easily as it clarifies. The panel unpacks the gap between rating-scale remission and how patients actually experience recovery, using real cases where appearances and scores diverged sharply.]]>Wed, 07 Oct 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/personalizing-mdd-treatment-evidence-experience-and-patient-valueshttps://www.psychiatrictimes.com/view/personalizing-mdd-treatment-evidence-experience-and-patient-values<![CDATA[Precision medicine looks different in psychiatry than in oncology. The panel discusses why personalizing MDD care starts with a complete patient history, and how clinical experience, evidence, and patient goals combine to guide treatment.]]>Wed, 07 Oct 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/sexual-dysfunction-in-depression-assessing-pleasure-alongside-desire-arousal-and-orgasmhttps://www.psychiatrictimes.com/view/sexual-dysfunction-in-depression-assessing-pleasure-alongside-desire-arousal-and-orgasm<![CDATA[Anita Clayton, MD, explains why sexual dysfunction affects most patients with major depression and how it overlaps with anhedonia.]]>Tue, 06 Oct 2026 20:30:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/running-a-sustainable-esketamine-treatment-center-for-trdhttps://www.psychiatrictimes.com/view/running-a-sustainable-esketamine-treatment-center-for-trd<![CDATA[Led by the moderator, the panelists examine how to build a center that lasts.]]>Tue, 06 Oct 2026 16:02:51 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/advice-for-clinicians-considering-an-interventional-trd-practicehttps://www.psychiatrictimes.com/view/advice-for-clinicians-considering-an-interventional-trd-practice<![CDATA[Led by the moderator, the panelists examined the rewards and demands of interventional care.]]>Tue, 06 Oct 2026 16:02:49 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/building-an-interventional-trd-practice-from-setup-to-the-patient-experiencehttps://www.psychiatrictimes.com/view/building-an-interventional-trd-practice-from-setup-to-the-patient-experience<![CDATA[Led by the moderator, the panelists discuss the legal, insurance credentialing, DEA licensure, REMS certification, and medication-acquisition steps behind opening a ketamine and esketamine practice, followed by staffing, systems, and outreach.]]>Tue, 06 Oct 2026 16:02:48 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/safety-monitoring-and-treatment-continuation-with-esketamine-in-trdhttps://www.psychiatrictimes.com/view/safety-monitoring-and-treatment-continuation-with-esketamine-in-trd<![CDATA[The expert psychiatrist examined safety as a layered process that begins with a trusting therapeutic relationship, continues with screening for medical contraindications and coordination with other clinicians, and extends to set, setting, and on-site emergency equipment.]]>Tue, 06 Oct 2026 16:02:46 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/choosing-between-ketamine-and-esketamine-in-trdhttps://www.psychiatrictimes.com/view/choosing-between-ketamine-and-esketamine-in-trd<![CDATA[Led by the moderator, the expert psychiatrist examined how he matches patients to each agent.]]>Tue, 06 Oct 2026 16:02:45 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/esketamine-in-trd-the-evidence-base-and-the-cost-critiquehttps://www.psychiatrictimes.com/view/esketamine-in-trd-the-evidence-base-and-the-cost-critique<![CDATA[Led by the moderator, the expert psychiatrist discusses the TRANSFORM and SUSTAIN trials as the strongest evidence for esketamine and notes that the requirement for a concomitant oral antidepressant has since been lifted.]]>Tue, 06 Oct 2026 16:02:43 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/the-case-for-early-muscarinic-therapy-in-schizophreniahttps://www.psychiatrictimes.com/view/the-case-for-early-muscarinic-therapy-in-schizophrenia<![CDATA[Real-world results and a personal caregiver's story build the case for starting a muscarinic agonist earlier, even at first break, rather than waiting until other options are exhausted.]]>Tue, 06 Oct 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/rethinking-long-standing-adhd-medication-regimenshttps://www.psychiatrictimes.com/view/rethinking-long-standing-adhd-medication-regimens<![CDATA[A regimen that has worked for twenty years may still be leaving symptoms untreated. The panel makes the case for revisiting long-standing ADHD prescriptions in light of newer technology.]]>Tue, 06 Oct 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/muscarinic-agonism-in-schizophrenia-mechanism-and-strategyhttps://www.psychiatrictimes.com/view/muscarinic-agonism-in-schizophrenia-mechanism-and-strategy<![CDATA[A newly approved muscarinic agonist offers a genuinely different mechanism for treating schizophrenia. The panel explains how it works and why most are choosing to add it rather than switch.]]>Tue, 06 Oct 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/moving-beyond-spot-treatment-to-all-day-adhd-controlhttps://www.psychiatrictimes.com/view/moving-beyond-spot-treatment-to-all-day-adhd-control<![CDATA[Treating ADHD only during visible hours leaves patients unprotected at the moments that matter most. The panel argues for symptom control that extends through bedtime, not just the workday.]]>Tue, 06 Oct 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/interventional-options-for-trd-ect-tms-and-esketaminehttps://www.psychiatrictimes.com/view/interventional-options-for-trd-ect-tms-and-esketamine<![CDATA[The expert psychiatrist examined structured programs such as inpatient, partial hospitalization, and intensive outpatient care, then described how electroconvulsive therapy and transcranial magnetic stimulation work. ]]>Mon, 05 Oct 2026 18:43:58 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/defining-treatment-resistant-depression-in-adultshttps://www.psychiatrictimes.com/view/defining-treatment-resistant-depression-in-adults<![CDATA[Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.]]>Mon, 05 Oct 2026 18:40:19 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/brain-trust-an-interventional-psychiatry-deep-dive-with-lisa-harding-mdhttps://www.psychiatrictimes.com/view/brain-trust-an-interventional-psychiatry-deep-dive-with-lisa-harding-md<![CDATA[Explore how clinicians weigh ECT, TMS, ketamine, and vagus nerve stimulation for treatment-resistant depression—balancing speed, access, durability, and patient preference.]]>Mon, 05 Oct 2026 17:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/deprescribing-in-psychiatry-a-systematic-approach-to-polypharmacyhttps://www.psychiatrictimes.com/view/deprescribing-in-psychiatry-a-systematic-approach-to-polypharmacy<![CDATA[Before adding another medication, review the diagnosis, the symptoms being targeted, and any drugs prescribed only to offset adverse effects.]]>Mon, 05 Oct 2026 15:00:00 GMTPsychiatric TimesusPsychiatric Times Articles